Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2)
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 848
- 主要终点
- Stroke or systemic embolism
研究概览
简要总结
People receiving dialysis are more likely to develop atrial fibrillation (AF), an irregular heartbeat that increases the risk of stroke. Blood-thinning medications (anticoagulants) are commonly used to prevent strokes in people with AF, but it is not known whether they are beneficial for people receiving dialysis because this group has not been well represented in previous clinical trials. As a result, healthcare providers do not have clear evidence to guide treatment decisions.
The SAFE-D2 study will compare two approaches to preventing stroke in adults receiving maintenance hemodialysis or peritoneal dialysis who have non-valvular AF and are at increased risk of stroke. Participants will be randomly assigned (by chance) to receive either apixaban, an oral blood thinner, or no oral anticoagulant, while continuing to receive their usual dialysis and medical care.
The main goal of the study is to determine whether apixaban is more effective than no oral anticoagulant at reducing the risk of stroke or blood clots traveling to other parts of the body (systemic embolism). The study will also compare the two approaches with respect to survival, heart-related complications, major bleeding and other bleeding events, hospitalizations, dialysis access complications, quality of life, and the overall balance of benefits and risks.
Approximately 848 participants from Canada, Brazil, and Israel will take part in the study. The results of SAFE-D2 are expected to provide important evidence to help patients, families, and healthcare providers make informed decisions about stroke prevention for people receiving dialysis who have atrial fibrillation.
详细描述
Atrial fibrillation (AF) is common among people receiving maintenance dialysis and is associated with an increased risk of ischemic stroke, systemic embolism, cardiovascular events, and death. Although oral anticoagulation is recommended for many patients with AF in the general population, the benefits and risks of anticoagulation in people receiving dialysis remain uncertain because this population has been excluded from most pivotal randomized trials. Observational studies have reported conflicting findings, and current guideline recommendations differ, resulting in substantial variation in clinical practice.
The Strategies for the Management of Atrial Fibrillation in patiEnts receiving Dialysis 2 (SAFE-D2) trial is designed to address this important evidence gap. The study will evaluate whether a treatment strategy using apixaban is superior to a strategy of no oral anticoagulation for the prevention of ischemic stroke and systemic embolism in adults receiving maintenance hemodialysis or peritoneal dialysis who have non-valvular AF and an elevated risk of stroke.
SAFE-D2 is an investigator-initiated, international, multicenter, pragmatic, randomized, open-label trial with blinded adjudication of study outcomes. Approximately 848 participants will be randomly assigned in a 1:1 ratio to receive either apixaban or no oral anticoagulation, while continuing to receive standard dialysis and other routine medical care.
The trial is designed to determine whether apixaban reduces the risk of ischemic stroke or systemic embolism while evaluating the overall balance between potential benefits and harms. In addition to thromboembolic events, the study will assess mortality, cardiovascular events, bleeding complications, hospitalizations, dialysis vascular access thrombosis, and patient-reported health-related quality of life. An independent Clinical Events Committee, blinded to treatment allocation, will adjudicate all major efficacy and safety outcomes according to prespecified definitions.
SAFE-D2 builds on the feasibility established in the CIHR-funded SAFE-D pilot trial and reflects contemporary clinical practice by evaluating apixaban rather than warfarin. The results are expected to provide high-quality randomized evidence to inform clinical practice guidelines and support shared decision-making regarding stroke prevention in people receiving maintenance dialysis and atrial fibrillation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be eligible to participate in this trial, participants need to satisfy ALL these inclusion criteria:
- •Age ≥18 years,
- •Kidney failure treated with hemodialysis or peritoneal dialysis for at least 90 days,
- •A history of non-valvular AF or atrial flutter (AFL) defined as one of the following:
- •AF/AFL on an ECG at enrollment.
- •≥2 episodes of AF/AFL on cardiac diagnostics with each episode lasting ≥30 seconds and occurring ≥24 hours apart.
- •One episode of AF/AFL on cardiac diagnostics lasting ≥30 seconds, plus ≥1 separate documented episode in the medical record.
- •One episode of AF (reported by cardiac diagnostics or documented in the medical record) plus treatment with an oral anticoagulant for stroke prevention as a result of AF/AFL; or
- •AF/AFL documented on one occasion in a cardiologist report.
- •Meet the CHA2DS2-VASc criteria (i.e. ≥2 for men and ≥3 for women)
排除标准
- •Potential participants must have NONE of the following exclusion criteria:
- •Mitral stenosis described as moderate or severe.
- •Anticoagulation indicated for a reason other than atrial fibrillation.
- •Receipt of aspirin at a dose of >160 mg daily.
- •Ongoing requirement at screening for a strong CYP3A4/P-gp inhibitor or inducer that cannot be discontinued, substituted, or otherwise managed safely.
- •Ongoing requirement for dual antiplatelet therapy at the time of screening that, in the judgement of the treating clinician, is expected to remain necessary after randomization and cannot be safely de-escalated to single antiplatelet therapy in the event of randomization to apixaban.
- •Known clinically significant coagulopathy, or other bleeding risk that, in the judgment of the treating physician, renders oral anticoagulation unsafe.
- •A major bleeding event in the 30 days prior to study enrollment, or any active and clinically significant bleeding.
- •Current pregnancy or breastfeeding.
- •Anticipated life expectancy < 6 months.
- •A scheduled live donor kidney transplant in the next 6 months.
- •Co-enrollment in a clinical trial where the intervention is deemed to interfere with the adherence, safety or efficacy of the SAFE-D2 treatment strategies
- •The treating clinical team has determined that long-term OAC is clearly indicated such that randomization to the no OAC strategy would not be clinically acceptable.
- •The treating clinical team has determined that long-term OAC is clearly contraindicated such that randomization to the apixaban strategy would not be clinically acceptable.
研究组 & 干预措施
Apixiban
The default starting dose of apixaban is 5 mg twice daily.
Dose reduction to 2.5 mg twice daily is mandatory for participants who meet either of the following criteria at baseline or at any point during follow-up:
- Age ≥80 years
- Dialysis target (dry) weight ≤60 kg
干预措施: Eliquis (Drug)
No oral anticoagulation
Individuals in this arm will be exposed to a treatment strategy in which no oral anticoagulation is prescribed.
干预措施: No oral anticoagulation (Other)
结局指标
主要结局
Stroke or systemic embolism
时间窗: 5 years
The primary outcome is time to first confirmed ischemic stroke or systemic embolism.
次要结局
- Time to all-cause death(5 years)
- Time to first occurrence of ischemic stroke, systemic embolism, or all-cause death(5 years)
- Time to first occurrence of ischemic stroke, systemic embolism, or cardiovascular death(5 years)
- Time to first occurrence of ischemic stroke, systemic embolism, myocardial infarction, or all-cause death(5 years)
- Time to first ischemic stroke(5 years)
- Time to first systemic embolism(5 years)
- Time to cardiovascular death(5 years)
- Time to first myocardial infarction(5 years)
- Net clinical benefit defined as the composite of stroke, systemic embolism, or major bleeding (ISTH definition).(5 years)
- Time to first dialysis vascular access thrombosis(5 years)
- Time to first major bleeding event(5 years)
- Time to first major or clinically relevant non-major bleeding event(5 years)
- Time to first clinically relevant non-major bleeding event(5 years)
- Time to first intracranial hemorrhage(5 years)
- Time to fatal bleeding(5 years)
- Number of all-cause unplanned hospitalizations(5 years)
研究者
Ziv Harel
Principal Investigator
Unity Health Toronto